Select Medical Taken Private by WCAS-Led Consortium for ~$3.9 Billion

On July 1, 2026, Select Medical Holdings Corporation completed its merger with a consortium led by Welsh, Carson, Anderson & Stowe (WCAS) and including company founders Robert A. Ortenzio and Martin F. Jackson. The transaction — valued at approximately $3.9 billion, or $16.50 per share in cash — represents one of the most significant management-led take-private transactions in U.S. healthcare services in recent years.

Parties: Select Medical Holdings Corporation (target) / Welsh, Carson, Anderson & Stowe-led consortium including Robert A. Ortenzio (Co-CEO) and Martin F. Jackson (CFO)

Sector: Healthcare services — critical illness recovery hospitals, inpatient rehabilitation hospitals, outpatient physical therapy

Transaction value: ~$3.9 billion; $16.50 per share in cash

Status: Closed July 1, 2026. Select Medical delisted from NYSE effective the same date.

As of March 31, 2026, Select Medical operated 103 critical illness recovery hospitals, 41 inpatient rehabilitation hospitals, and 1,912 outpatient rehabilitation clinics across the United States — making this a transaction of significant scale within U.S. healthcare infrastructure.

The participation of Select Medical's co-founder and CFO alongside the financial sponsor creates a classic management rollover / insider-led acquisition structure. This is distinct from a pure financial sponsor buyout: the founders retain a meaningful equity stake in the surviving private entity, aligning their incentives with the new ownership structure while providing the acquirer with operational continuity and institutional knowledge.

For Turkish companies evaluating U.S. acquisitions, this structure illustrates how management retention can be structured as equity participation rather than employment agreements alone — a critical distinction in U.S. M&A practice.

Because the transaction involved company insiders (the founders) on both sides of the deal — as sellers of their public shares and as equity participants in the acquiring consortium — the Select Medical board formed an independent special committee to evaluate the transaction and negotiate on behalf of unaffiliated shareholders.

The special committee retained Goldman Sachs as financial advisor and Skadden, Arps, Slate, Meagher & Flom as legal counsel. This dual-advisor structure (investment bank + M&A law firm) is standard practice for special committees in transactions involving potential conflicts of interest.

Key special committee responsibilities included:

• Evaluating the fairness of the $16.50 per share consideration
• Negotiating deal terms and protections for minority shareholders
• Overseeing the go-shop or market check process
• Recommending (or not) the transaction to the full board

Select Medical shareholders approved the merger at a special meeting held on June 26, 2026. The transaction closed five days later on July 1, 2026 — a tight but achievable timeline given that regulatory approvals (HSR antitrust clearance, state healthcare regulatory approvals) had been obtained in advance.

J.P. Morgan and Wells Fargo served as debt financing arrangers for the acquisition. In a take-private of this scale, the debt financing package typically includes:

• Term Loan B (TLB): Senior secured term loan, often the largest component
• Revolving credit facility: For ongoing working capital needs
• Potentially high-yield notes: Depending on leverage targets and market conditions

The healthcare sector presents specific considerations for debt financing: revenue concentration in Medicare/Medicaid reimbursement creates regulatory risk that lenders price into covenants and interest rates. Select Medical's mix of critical illness recovery and rehabilitation services — both heavily reimbursed by federal programs — would have been a central focus of lender due diligence.

A go-private transaction removes a public company from stock exchange listing and SEC reporting obligations. The mechanics involve:

• Merger agreement between the target and an acquisition vehicle controlled by the buyer
• Proxy statement / Schedule 14A filed with the SEC, sent to shareholders
• Shareholder vote at a special meeting (typically requires majority of outstanding shares)
• Closing and delisting: Upon merger effectiveness, shares are cancelled and shareholders receive cash consideration; the company files a Form 15 to deregister with the SEC

For Turkish companies that have listed or are considering listing subsidiaries on U.S. exchanges, understanding go-private mechanics is essential for exit planning.

Following the merger's effectiveness on July 1, 2026, Select Medical's shares ceased trading on the New York Stock Exchange. The delisting process involves:

• Notification to NYSE of the merger closing
• Suspension of trading
• Filing of Form 25 (Notification of Removal from Listing) with the SEC
• Filing of Form 15 to deregister the class of securities

Post-delisting, the company is no longer subject to NYSE listing standards, SEC periodic reporting requirements (10-K, 10-Q, 8-K), or Sarbanes-Oxley Section 404 auditor attestation requirements — a significant reduction in compliance burden and cost.

Healthcare take-privates involve regulatory dimensions beyond standard M&A:

• Certificate of Need (CON) laws: Many states require regulatory approval before hospitals can be acquired, transferred, or have their ownership changed
• Medicare/Medicaid provider agreements: Change of ownership (CHOW) notifications must be filed with CMS; provider agreements may need to be re-enrolled
• State healthcare licensing: Hospital licenses are typically not transferable and must be re-applied for in the new entity's name
• Anti-kickback and Stark Law compliance: Restructuring physician relationships post-acquisition requires careful compliance review

When management participates on both sides of a transaction, Delaware courts (and the courts of other states) apply heightened scrutiny. The entire fairness standard — rather than the more deferential business judgment rule — may apply if the transaction is not properly structured. Key protections include:

• Independent special committee with full authority to negotiate and reject
• Majority-of-the-minority shareholder vote condition
• Robust market check (go-shop period)
• Fairness opinion from an independent financial advisor

The Select Medical transaction incorporated these protections, as evidenced by the special committee structure and Goldman Sachs fairness opinion.

Turkish companies and investors active in U.S. healthcare services — or evaluating entry into this sector — should note several practical takeaways from this transaction:

For acquirers: The management rollover structure can be an effective tool for retaining operational leadership post-acquisition, particularly in service businesses where key relationships and institutional knowledge are concentrated in the founding team.

For sellers: The special committee process and majority-of-the-minority vote condition provide meaningful protections for public shareholders in conflicted transactions — but they also extend the timeline and increase transaction costs.

For debt financing: Healthcare reimbursement risk (Medicare/Medicaid rate changes, coverage policy shifts) is a primary focus of lender due diligence in healthcare acquisitions. Turkish companies should be prepared to address this risk in detail during financing negotiations.

For regulatory planning: State-by-state healthcare licensing and CON requirements can significantly extend the pre-closing regulatory approval timeline. Early engagement with state health departments is essential.

ULF New York advises Turkish companies and investors on U.S. market entry, M&A transactions, corporate structuring, and cross-border legal matters. Contact us for a consultation on U.S. healthcare acquisitions or private equity transactions.